{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:36:37Z","timestamp":1777080997609,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11255-021-02950-3","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T18:02:36Z","timestamp":1626804156000},"page":"895-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of high- vs low-dose native vitamin D on albuminuria and the renin\u2013angiotensin\u2013aldosterone system: a randomized pilot study"],"prefix":"10.1007","volume":"54","author":[{"given":"Thierry","family":"Krummel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Ingwiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Charlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doroth\u00e9e","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-8260","authenticated-orcid":false,"given":"Thierry","family":"Hannedouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"issue":"1","key":"2950_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2010.531","volume":"80","author":"RT Gansevoort","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS et al (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80(1):93\u2013104","journal-title":"Kidney Int"},{"key":"2950_CR2","doi-asserted-by":"crossref","unstructured":"The GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349(9069):1857\u20131863","DOI":"10.1016\/S0140-6736(96)11445-8"},{"issue":"12","key":"2950_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 Diabetes and nephropathy. N Engl J Med 345(12):861\u2013869","journal-title":"N Engl J Med"},{"issue":"6","key":"2950_CR4","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1046\/j.1523-1755.2003.00033.x","volume":"63","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P, Perna A, Remuzzi G, Investigators of the Gisen Group (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63(6):2254\u20132261","journal-title":"Kidney Int"},{"key":"2950_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1681\/ASN.2007060693","volume":"19","author":"L Vogt","year":"2008","unstructured":"Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G (2008) Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19:999\u20131007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2950_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ki.1989.190","volume":"36","author":"JE Heeg","year":"1989","unstructured":"Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D (1989) Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36(2):272\u2013279","journal-title":"Kidney Int"},{"issue":"1","key":"2950_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2012","unstructured":"Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P (2012) Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 23(1):165\u2013173","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2950_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"Y Li","year":"2002","unstructured":"Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L (2002) 1,25 dihydroxyvitamin D3 is a negative regulator of renin angiotensin system. J Clin Invest 110(2):229\u2013238","journal-title":"J Clin Invest"},{"key":"2950_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ki.2008.101","volume":"74","author":"C Zhou","year":"2008","unstructured":"Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D (2008) Calcium-independent and 1,25(OH) 2 D 3 -dependent regulation of the renin-angiotensin system in 1a-hydroxylase knockout mice. Kidney Int 74:170\u2013179","journal-title":"Kidney Int"},{"issue":"41","key":"2950_CR10","doi-asserted-by":"publisher","first-page":"29821","DOI":"10.1074\/jbc.M705495200","volume":"282","author":"W Yuan","year":"2007","unstructured":"Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE et al (2007) 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282(41):29821\u201329830","journal-title":"J Biol Chem"},{"issue":"11","key":"2950_CR11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/ki.2008.408","volume":"74","author":"M Freundlich","year":"2008","unstructured":"Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR et al (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74(11):1394\u20131402","journal-title":"Kidney Int"},{"issue":"5","key":"2950_CR12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1161\/HYPERTENSIONAHA.109.148619","volume":"55","author":"JP Forman","year":"2010","unstructured":"Forman JP, Williams JS, Fisher NDL (2010) Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55(5):1283\u20131288","journal-title":"Hypertension"},{"issue":"11","key":"2950_CR13","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/jhh.2010.110","volume":"25","author":"A Vaidya","year":"2011","unstructured":"Vaidya A, Forman JP, Williams JS (2011) Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens 25(11):672\u2013678","journal-title":"J Hum Hypertens"},{"issue":"3","key":"2950_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1470320310391922","volume":"12","author":"A Vaidya","year":"2011","unstructured":"Vaidya A, Forman JP, Hopkins PN, Seely EW, Williams JS (2011) 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 12(3):311\u2013319","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"2","key":"2950_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.ki.5002572","volume":"73","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J et al (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73(2):163\u2013171","journal-title":"Kidney Int"},{"issue":"6","key":"2950_CR16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68(6):2823\u20132828","journal-title":"Kidney Int"},{"issue":"2","key":"2950_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z et al (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial. Hypertension 52(2):249\u2013255","journal-title":"Hypertension"},{"issue":"9752","key":"2950_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D De Zeeuw","year":"2010","unstructured":"De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 376(9752):1543\u20131551","journal-title":"Lancet"},{"issue":"4","key":"2950_CR19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","volume":"54","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54(4):647\u2013652","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"2950_CR20","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1681\/ASN.2013030203","volume":"24","author":"MH de Borst","year":"2013","unstructured":"de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJA (2013) Active vitamin D treatment for reduction of residual proteinuria: a systematic review. J Am Soc Nephrol 24(11):1863\u20131871","journal-title":"J Am Soc Nephrol"},{"key":"2950_CR21","doi-asserted-by":"crossref","unstructured":"Keyzer CA, van Breda GF, Vervloet MG, de Jong MA, Laverman GD, Hemmelder MH, et al. Holland Nephrology Study (HONEST) Network (2016) Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: the ViRTUE-CKD trial. J Am Soc Nephrol 1\u201310","DOI":"10.1681\/ASN.2016040407"},{"issue":"8","key":"2950_CR22","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ki.2011.224","volume":"80","author":"M Kim","year":"2011","unstructured":"Kim M, Frankel A, Donaldson M, Darch SJ, Pusey CD, Hill PD et al (2011) Oral cholecalciferol decreases albuminuria and urinary TGF-\u03b21 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 80(8):851\u2013860","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"2950_CR23","first-page":"S41","volume":"95","author":"U Krairittichai","year":"2012","unstructured":"Krairittichai U, Mahannopkul R, Bunnag S (2012) An open label, randomized controlled study of oral calcitriol for the treatment of proteinuria in patients with diabetic kidney disease. J Med Assoc Thai 95(Suppl 3):S41\u2013S47","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"2950_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.ajkd.2011.09.014","volume":"59","author":"LJ Liu","year":"2012","unstructured":"Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY (2012) Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 59(1):67\u201374","journal-title":"Am J Kidney Dis"},{"key":"2950_CR25","doi-asserted-by":"crossref","unstructured":"Holick MF (2007) Vitamin D deficiency. New Engl J Med 357:266\u2013281","DOI":"10.1056\/NEJMra070553"},{"key":"2950_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ajcn\/77.1.204","volume":"77","author":"RP Heaney","year":"2003","unstructured":"Heaney RP, Davies M, Chen TC, Holick MF, Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol 1\u20133. Am J Clin Nutr 77:204\u2013210","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2950_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/jn\/136.4.1117","volume":"136","author":"R Vieth","year":"2006","unstructured":"Vieth R (2006) Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 136(4):1117\u20131122","journal-title":"J Nutr"},{"key":"2950_CR28","unstructured":"Suitor CW, Meyers LD (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D. Insitute of Medicine, Dietary Reference Intakes, pp 19\u201334"},{"issue":"4","key":"2950_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/01.CIR.92.4.825","volume":"92","author":"M Azizi","year":"1995","unstructured":"Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, M\u00e9nard J (1995) Additive effects of combined angiotensin-converting enzyme inhibition and Angiotensin II Antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 92(4):825\u2013834","journal-title":"Circulation"},{"issue":"6","key":"2950_CR30","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/HYPERTENSIONAHA.113.01196","volume":"61","author":"M Azizi","year":"2013","unstructured":"Azizi M, Blanchard A, Charbit B, Wuerzner G, Peyrard S, Ezan E et al (2013) Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers novelty and significance. Hypertension 61(6):1239\u20131245","journal-title":"Hypertension"},{"key":"2950_CR31","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","volume":"358","author":"H-H Parving","year":"2008","unstructured":"Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in Type 2 Diabetes and nephropathy. N Engl J Med 358:2433\u20132446","journal-title":"N Engl J Med"},{"issue":"1","key":"2950_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1212\/01.wnl.0000438226.10353.1c","volume":"82","author":"S Phillips Hey","year":"2014","unstructured":"Phillips Hey S, Kimmelman J (2014) The questionable use of unequal allocation in confirmatory trials. Neurology 82(1):77\u201379","journal-title":"Neurology"},{"issue":"1","key":"2950_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2005.08.003","volume":"27","author":"JC Dumville","year":"2006","unstructured":"Dumville JC, Hahn S, Miles JNV, Torgerson DJ (2006) The use of unequal randomization ratios in clinical trials: a review. Contemp Clin Trials 27(1):1\u201312","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"2950_CR34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","volume":"63","author":"SM Sprague","year":"2003","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63(4):1483\u20131490","journal-title":"Kidney Int"},{"issue":"4","key":"2950_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2165\/00003495-200565040-00008","volume":"65","author":"DM Robinson","year":"2005","unstructured":"Robinson DM, Scott LJ (2005) Paricalcitol: a review of its use in the management of secondary hyperparathyroidism. Drugs 65(4):559\u2013576","journal-title":"Drugs"},{"issue":"7","key":"2950_CR36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/ki.2010.387","volume":"79","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Zehnder D (2011) New vitamin D analogs and changing therapeutic paradigms. Kidney Int 79(7):702\u2013707","journal-title":"Kidney Int"},{"issue":"1","key":"2950_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ndt\/gft360","volume":"29","author":"P Molina","year":"2014","unstructured":"Molina P, G\u00f3rriz JL, Molina MD, Peris A, Beltr\u00e1n S, Kanter J et al (2014) The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: a prospective controlled study. Nephrol Dial Transpl 29(1):97\u2013109","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"2950_CR38","doi-asserted-by":"publisher","first-page":"e50510","DOI":"10.1371\/journal.pone.0050510","volume":"7","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yu H, Lu J, Guo K, Zhang L, Bao Y et al (2012) Oral supplementation with cholecalciferol 800 IU ameliorates albuminuria in Chinese type 2 diabetic patients with nephropathy. PLoS ONE 7(11):e50510","journal-title":"PLoS ONE"},{"issue":"12","key":"2950_CR39","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2215\/CJN.03830415","volume":"10","author":"CA Keyzer","year":"2015","unstructured":"Keyzer CA, Lambers-Heerspink HJ, Joosten MM, Deetman PE, Gansevoort RT, Navis G, PREVEND Study Group et al (2015) Plasma Vitamin D level and change in albuminuria and eGFR according to sodium intake. Clin J Am Soc Nephrol 10(12):2119\u20132127","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2950_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamainternmed.2015.0237","volume":"175","author":"LA Beveridge","year":"2015","unstructured":"Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM et al (2015) Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med 175(5):745","journal-title":"JAMA Intern Med"},{"issue":"4","key":"2950_CR41","first-page":"1","volume":"35","author":"CJ McMullan","year":"2016","unstructured":"McMullan CJ, Borgi L, Curhan GC, Fisher N, Forman JP (2016) The effect of vitamin D on renin\u2013angiotensin system activation and blood pressure. J Hypertens 35(4):1","journal-title":"J Hypertens"},{"issue":"1\u20132","key":"2950_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jsbmb.2010.03.064","volume":"121","author":"A Dusso","year":"2010","unstructured":"Dusso A, Arcidiacono MV, Yang J, Tokumoto M (2010) Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 121(1\u20132):193\u2013198","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"110","key":"2950_CR43","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrneph.2014.49","volume":"10","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Wolf M (2014) Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10(110):268\u2013278","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2950_CR44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ndt\/gfw082","volume":"31","author":"DJA Goldsmith","year":"2016","unstructured":"Goldsmith DJA (2016) Pro: should we correct vitamin D deficiency\/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms? Nephrol Dial Transpl 31(5):698\u2013705","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"2950_CR45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ndt\/gfw080","volume":"31","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Georgianos PI (2016) Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transpl 31(5):706\u2013713","journal-title":"Nephrol Dial Transpl"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-021-02950-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-021-02950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T06:17:46Z","timestamp":1675577866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-021-02950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2950"],"URL":"https:\/\/doi.org\/10.1007\/s11255-021-02950-3","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,20]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors declare any conflict of interest for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}